Lucid Diagnostics (LUCD) announced its intention to offer shares of common stock through an underwritten public offering. Proceeds from the offering are expected to support working capital and general corporate purposes. Completion of the offering remains subject to market conditions, with no assurance regarding its timing, size, or terms. Canaccord Genuity is acting as the sole bookrunner of the offering and Maxim Group LLC is acting as co-manager of the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUCD:
- Lucid Diagnostics Earnings Call Highlights Growth and Challenges
- Lucid Diagnostics price target lowered to $2 from $2.50 at BTIG
- Lucid Diagnostics: Strong Growth Potential Driven by Strategic Advancements and Market Expansion
- Lucid Diagnostics Reports Strong Growth and Future Plans
- Lucid Diagnostics: Buy Rating Affirmed Amidst Strong Test Volume Growth and Anticipated Revenue Upsurge